Iduronate-2-sulfatase enzyme replacement therapy

Biologic

Iduronate-2-sulfatase enzyme replacement therapy is one of 27 biologic programs targeting Mucopolysaccharidosis. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

MucopolysaccharidosisActive, not recruiting

MucopolysaccharidosisPhase 2/Phase 3

Active, not recruiting

Competition

Competitive Landscape

34 competitors in Mucopolysaccharidosis

#DrugCompanyPhaseTrials

Rituxan

Roche

Approved

1 2

Trexall

Alnylam Pharmaceuticals

Approved

1 3

Neoral

Immunoglobulin

1 5

Imuran

LLegacy Health System

Approved

—6

BMN 333

BioMarin Pharmaceutical

Phase 3

5 7

ELAPRASE

Takeda

Approved

2 8

ELAPRASE

Takeda

Phase 3

2 9

Humira

CCelltrion

Phase 2

1 10

Genotropin

EMD Serono

Phase 2

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Mucopolysaccharidosis1 trial

Iduronate-2-sulfatase Enzyme Replacement Therapy in Mucopolysaccharidosis II (MPS II)

Completed· Takeda logo

Takeda·Phase 2/3·NCT00069641·96 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Iduronate-2-sulfatase enzyme replacement therapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Iduronate-2-sulfatase enzyme replacement therapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Iduronate-2-sulfatase enzyme replacement therapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Takeda company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Company: Takeda

Iduronate-2-sulfatase enzyme replacement therapy

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Mucopolysaccharidosis1 trial

References

Drug Info

Quick Facts

Related News